Of a subset of 77 women with HER2-positive breast cancer from the NEO-ALTTO study receiving neoadjuvant lapatinib and trastuzumab for 6 weeks (followed by 12 weeks of paclitaxel), those with metabolic changes in tumours identified by FDG-PET at week 2 and week 6 were twice as likely to achieve a pathological complete response at the time of surgery 12 weeks later [30]. This evidence concerns the gene ERBB2 and breast cancer.